Clinical Trials

Clinical Trials Underway at CSU

A great deal of test data and anecdotal evidence indicates that cannabinoids provide animals with symptomatic relief from a range of medical conditions. Specifically, the most recent report, addressed many issues in great detail. However, none of the products currently on the market has been studied under the standards required by regulatory authorities such as the Food and Drug Administration (“FDA”), proving that they are safe and effective. Therefore, ABSC is sponsoring groundbreaking clinical trials at CSU.

ABSC sponsored a Phase 1 study to investigate the safety of specified combinations and delivery methods in dogs. Study results presented at the Institute of Cannabis Research Conference at CSU-Pueblo on April 29, 2017 indicated that dogs tolerated clinical doses without adverse effects. Research results should be published in 2018.

ABSC’s proprietary premium pet product is created from concentrated, organically-grown Colorado Hemp Oil extract. This product is undergoing rigorous testing at Colorado State University’s College of Veterinary Medicine and Biomedical Sciences (“CSU”). Currently there are multiple clinical trials underway at CSU to test this product’s usefulness for a variety of common ailments, including epilepsy, pain relief and arthritis. This is a full-spectrum high cannabinoid whole-plant hemp extract.

ABSC’s Phase 2 clinical trials have begun, October 2016, and will study the efficacy of CHO in the treatment of selected medical conditions. The specific medical conditions include:

  • Osteoarthritis and chronic pain

  • Epilepsy and seizure disorders